AD research faces brutal validation standards. For good reason.
Biomarker validation pressure
Amyloid, tau, neurofilament light — which biomarker claims replicate across cohorts? Which are overfitted to specific populations?
Trial failure rates are brutal
AD trials fail at 99%+ rates. Evidence synthesis before Phase 2 commitment catches weak hypotheses early.
Mechanism claims need scrutiny
Neuroinflammation, synaptic dysfunction, protein aggregation — mechanism claims need verified evidence, not optimistic extrapolation.
Adversarial review before publication or trial commitment.
Multi-model adversarial review
Independent model families attack your claims from different architectural perspectives, producing a claim-support audit and independent contradiction memo. No single model's blind spots.
Adversarial claim testing
Claims that survive multi-model adversarial attack are stronger submissions. Claims that don't survive save you a trial cycle.
Citation verification
Every DOI is checked against live databases before delivery. Fabricated or mismatched references are flagged.
What the pipeline produces.
Pre-trial adversarial review: With 99%+ AD trial failure rates, the cost of a weak hypothesis is measured in years and millions. Multi-model adversarial attack surfaces weaknesses before you commit resources.
Research audit for Alzheimer's work.
Send one hypothesis, biomarker claim, or mechanism assertion. We run it through cross-architecture adversarial review.